Eternity in Medical Information -- Medisurf


Search \| Web Directory, News, Variable useful Information, PubMed In Medine, All

Category Select :

Items 81 ~ 100 of 25816, Page 5 of 1292

81. U.S. FDA Accepts sNDAs for PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate)

Potential New Indication Would Expand Use to Allow Treatment-Experienced Adults Living with HIV-1 Whose Virus is Suppressed to Switch to PIFELTRO (in Combination with Other Antiretrovirals) or DELSTRIGO

01/22/2019 MERCK

82. Patient-Level Survival Analysis Demonstrates No Link Between Paclitaxel Dose and Mortality in Patients Treated with IN.PACT Admiral DCB

Data Presented Today at LINC Reiterate Commitment to Patient Safety and Data Transparency

01/22/2019 Medtronic

83. Study: Oncologists Want More Education About LGBTQ Issues

A survey of oncologists finds that most say they don’t know enough about how to treat people in the lesbian, gay, bisexual, transgender, and queer/questioning (LGBTQ) community, but want to learn more.

01/22/2019 American Cancer Society

84. Trampoline parks may cause more severe trauma than at home trampoline use

New research compares injuries sustained at commercial jump parks versus home trampolines

01/22/2019 American Academy of Orthopaedic Surgeons

85. Lifestyle Choices May Help Glaucoma Patients Preserve Eyesight

American Academy of Ophthalmology offers advice on how people can take control of their health beyond medications and surgery

01/22/2019 American Academy of Ophthalmology

86. Abbott Offers a New Option for Physicians Treating Patients with Atrial Fibrillation

With approval of the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™, Abbott is helping more physicians integrate ablation with 3D mapping to advance the treatment of people with atrial fibrillation

01/21/2019 Abbott

87. New Data Reinforce Benefits of Abbott’s BurstDR™ Spinal Cord Stimulation for People Living with Chronic Pain

Data from two recent studies presented at NANS 2019 demonstrate key benefits of BurstDR™ stimulation / Microdosing BurstDR stimulation at lowest effective energy allows patients to manage their pain without the burden of recharging their devices / Additional data further showed switching from other types of SCS therapies to Abbott’s BurstDR stimulation significantly reduced pain and the need for opioid medication

01/19/2019 Abbott

88. ACS Cancer Prevention Blueprint Targets Controllable Risk Factors

This second chapter in the American Cancer Society Cancer Control Blueprint describes what we know about risk factors for cancer. It provides strategies people can use to help avoid those risk factors. It also offers strategies that cities, states, and communities can use to help people avoid them. It''s co-authored by staff researcher Susan Gapstur, PhD, MPH, senior vice president of Behavioral and Epidemiology Research.

01/18/2019 American Cancer Society

89. American Academy of Orthopaedic Surgeons approves clinical practice guideline for management of acute compartment syndrome

Evidence-based diagnosis and treatment recommendations for traumatic, severe limb injuries

01/17/2019 American Academy of Orthopaedic Surgeons

90. Statement from FDA Commissioner, on unprecedented new efforts to support development of over-the-counter naloxone to help reduce opioid overdose deaths

01/17/2019 U.S. FOOD & DRUG ADMINISTRATION

91. World Cancer Day 2019: ‘I Am and I Will.’

Monday, February 4th is World Cancer Day, when organizations and people around the world unite to raise awareness about cancer and work to make it a global health priority.

01/17/2019 American Cancer Society

92. Medtronic Enrolls First Patient in Clinical Study to Assess Pain Control and Oral Opioid Elimination with Targeted Drug Delivery

Study Will Further Advance Understanding of Effectiveness and Tolerability of the SynchroMed(TM) II Intrathecal Drug Delivery System in Patients Who Have Weaned off Oral Opioids

01/17/2019 Medtronic

93. Japanese Red Cross Society Selects Abbott Technology to Screen Country''s Blood and Plasma Supply

LONG-TERM AGREEMENT BETWEEN JAPANESE RED CROSS SOCIETY AND ABBOTT BRINGS TOGETHER TWO GLOBAL LEADERS IN BLOOD AND PLASMA SCREENING, HELPING ENSURE A SAFE AND EFFICIENT BLOOD SUPPLY ACROSS JAPAN

01/17/2019 Abbott

94. FDA approves first generic version of Sabril to help treat seizures in adults and pediatric patients with epilepsy

01/16/2019 U.S. FOOD & DRUG ADMINISTRATION

95. Abbott To Acquire Cephea Valve Technologies, Inc.

Acquisition to further bolster Abbott's leading position in therapies for mitral valve disease, the most common type of heart valve ailment

01/16/2019 Abbott

96. Statement from FDA Commissioner, Director of the Center for Biologics Evaluation and Research on new policies to advance development of safe and effective cell and gene therapies

01/15/2019 U.S. FOOD & DRUG ADMINISTRATION

97. Medtronic Launches Mobile App That Communicates Directly with World''s First Smartphone-Connected Pacemakers

MyCareLink Heart(TM) Mobile App Allows Pacemaker Patients to Easily Stay Connected with Their Clinics

01/15/2019 Medtronic

98. Personalized Treatment Benefits Kidney Cancer Patients

Patients who have risk factors for worsening kidney disease may benefit from personalized treatment plans / Researchers constructed a simulation model to assess the impact of different treatment approaches in patients with small renal tumors. /

01/15/2019 Radiological Society of North America

99. AAOS Praises Introduction of Hospital Competition Act

01/15/2019 American Academy of Orthopaedic Surgeons

100. Merck’s KEYTRUDA® (pembrolizumab) Reduced Risk of Death by 31 Percent Compared to Chemotherapy in Previously Treated Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Expressed PD-L1 (CPS ≥10)

Results from Phase 3 KEYNOTE-181 Trial to be Presented at 2019 Gastrointestinal Cancers Symposium (ASCO GI)

01/14/2019 MERCK

경기도 성남시 분당구 구미동 25-1 엘레강스 프라자 ㈜ 메디서프 | Tel : 031-896-0930 | 사업자 등록번호 : 212-81-47247
통신판매신호번호 : 경기 성남 2007-712 | 대표이사 한상욱